In this article, we will discuss Durvalumab (Clinical Trials Experience-3). So, let’s get started.
The data described in this section reflect exposure to Durvalumab in patients with Stage III NSCLC enrolled in the PACIFIC study, in patients with ES-SCLC enrolled in the CASPIAN study and in patients with BTC enrolled in the TOPAZ-1 study.